San Diego, Calif., May 6, 2023 – Sumit Garg, M.D., Vice Chair of Clinical Ophthalmology & Medical Director at the Gavin Herbert Eye Institute, University of California, Irvine presented the long-term (36 months) visual outcomes during scientific sessions on Presbyopia Correcting IOLs.
Providing both quantity (range) and quality of vision is what sets the Juvene® IOL apart from other presbyopia correcting IOLs. Key highlights of the data include good outcomes across the full visual range (distance, intermediate and near) are maintained for three years postoperatively. In addition, accommodative amplitude was maintained during the same period. Mesopic (low light) contrast sensitivity results for the Juvene® IOL are like that of a high quality monofocal (Tecnis) measured with same system and all bilateral patients are spectacles free.
According to Dr. Garg, “two important questions, besides safety, that the longer-term data has confirmed is the ability of the Juvene intraocular lens (IOL) to maintain refractive stability and accommodative amplitude over thirty-six months.”
ABOUT PRESBYOPIA AND CATARACTS
Presbyopia is the progressive loss of the natural lens’ ability to accommodate or change focus from far to near objects. It becomes noticeable in our early to mid-forties and continues to progress. Cataracts are the clouding of the natural lens which inhibits light from passing into the eye.
LensGen® is a clinical stage company headquartered in Irvine, California focused on restoring youthful vision to millions of cataract and presbyopia patients. With its innovative Juvene® modular fluid optic intraocular lens the company aims to treat vision correction errors and provide spectacle independence to patients affected by cataracts and/or presbyopia. For more information, please visit http://www.lensgen.com.
Juvene® Intraocular Lens is not approved by the FDA and it is not available for sale or use in the United States.